MedPath

The Challenge of Obtaining Qualitative Bacterial Cultures in Non-expectorating Cystic Fibrosis Patients

Completed
Conditions
Cystic Fibrosis
Interventions
Procedure: Nasal swab
Procedure: Cough swab
Procedure: Spontaneous expectorated sputum
Procedure: Induced sputum
Procedure: Bronchoalveolar lavage
Other: Questionnaire
Registration Number
NCT02363764
Lead Sponsor
Universitair Ziekenhuis Brussel
Brief Summary

Accurate identification of lower respiratory tract pathogens is standard of care in the management of CF patients and it is therefore recommended to perform regular bacterial cultures, at least once a year, but some even recommend monthly cultures. This can be done through different methods, of which sputum and bronchoalveolar lavage (BAL) are the gold standard. However, BAL is an invasive method, not designated to repeat monthly. Therefore, the diagnosis of lower respiratory tract infections can be challenging in the non-expectorating CF patient. Other methods, such as induced sputum (IS), cough swabs and nasal swabs, have been developed to obtain bacterial cultures in these patients. Studies have investigated the reliability of these different sampling methods, however, with controversial conclusions.

Detailed Description

I. Protocol design:

The current protocol is designed to compare:

* Group 1: nasal swab, cough swab and spontaneous expectorated sputum in expectorating CF patients

* Group 2: nasal swab, cough swab and induced sputum in non-expectorating CF patients

* Group 3: nasal swab, cough swab, induced sputum and BAL in both expectorating and non-expectorating CF patients requiring clinically indicated bronchoscopy

II. Flow chart:

1. Nasal swab obtained by the physiotherapyst (PT)

2. Patient rinses his mouth with water, followed by autogenic drainage

3. Cough swab obtained by the PT

4. Obtainment of 3rd (4th) sample:

* Group 1: Sputum sample voluntary expectorated by the patient

* Group 2 and 3: Induced sputum sample --\> voluntary coughed up and expectorated by the patient after inhalation of 4ml of HS OR

* Group 3: BAL --\>obtained by the pulmonologist during bronchoscopy

5. Filling out questionnaire on acceptability of the different sampling methods by patients \>6 years of age (not in Group 3)

III. Analysis of the samples:

(Induced) Sputum samples, cough and nasal swabs are aseptically collected in the appropriate disposable and are immediately sent to the Laboratory for Microbiology and Infection Control of the Universitair Ziekenhuis Brussel, where analyses are carried out within 24h post-sampling.

These analyses include:

* Culture and identification of respiratory pathogens on selective and non-selective media

* Each type of colony will be identified by MALDI-TOF mass spectrometry, completed by other identification tests if needed

* When appropriate, susceptibility tests will be performed on the isolated bacteria

IV. Statistical analysis:

* Determination of sensitivity, specificity, positive predicted value, negative predicted value of the different sampling methods

* Preference for one method over another: crosstabs, Chi-square test

* Pain experienced with any method (Yes/No): Student's t-test

* VAS-scale pain per method: ANOVA

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
175
Inclusion Criteria
  • Both expectorating and non-expectorating CF patients with confirmed diagnosis (sweat test / genotyping)
  • All ages
  • Attending the UZ Brussel CF Clinic
  • Written informed consent from each participant and/or his parents or legal guardian
Exclusion Criteria
  • CF patients who underwent lung transplantation
  • Denial of participation to the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Non-expectorating CF patientsNasal swab(=unable to expectorate sputum spontaneously) 1. Nasal swab 2. Cough swab 3. Induced sputum after inhalation of hypertonic saline (NaCl 6%) 4. Questionnaire
Expectorating CF patientsCough swab(=able to expectorate sputum spontaneously) 1. Nasal swab 2. Cough swab 3. Spontaneous expectorated sputum 4. Questionnaire
Expectorating CF patientsNasal swab(=able to expectorate sputum spontaneously) 1. Nasal swab 2. Cough swab 3. Spontaneous expectorated sputum 4. Questionnaire
Expectorating CF patientsSpontaneous expectorated sputum(=able to expectorate sputum spontaneously) 1. Nasal swab 2. Cough swab 3. Spontaneous expectorated sputum 4. Questionnaire
Bronchoscopy CF patientsBronchoalveolar lavage(=undergoing clinically indicated bronchoscopy) 1. Nasal swab 2. Cough swab 3. Induced sputum after inhalation of hypertonic saline (NaCl 6%) 4. Bronchoalveolar lavage (BAL)
Expectorating CF patientsQuestionnaire(=able to expectorate sputum spontaneously) 1. Nasal swab 2. Cough swab 3. Spontaneous expectorated sputum 4. Questionnaire
Bronchoscopy CF patientsNasal swab(=undergoing clinically indicated bronchoscopy) 1. Nasal swab 2. Cough swab 3. Induced sputum after inhalation of hypertonic saline (NaCl 6%) 4. Bronchoalveolar lavage (BAL)
Non-expectorating CF patientsQuestionnaire(=unable to expectorate sputum spontaneously) 1. Nasal swab 2. Cough swab 3. Induced sputum after inhalation of hypertonic saline (NaCl 6%) 4. Questionnaire
Bronchoscopy CF patientsCough swab(=undergoing clinically indicated bronchoscopy) 1. Nasal swab 2. Cough swab 3. Induced sputum after inhalation of hypertonic saline (NaCl 6%) 4. Bronchoalveolar lavage (BAL)
Non-expectorating CF patientsCough swab(=unable to expectorate sputum spontaneously) 1. Nasal swab 2. Cough swab 3. Induced sputum after inhalation of hypertonic saline (NaCl 6%) 4. Questionnaire
Non-expectorating CF patientsInduced sputum(=unable to expectorate sputum spontaneously) 1. Nasal swab 2. Cough swab 3. Induced sputum after inhalation of hypertonic saline (NaCl 6%) 4. Questionnaire
Bronchoscopy CF patientsInduced sputum(=undergoing clinically indicated bronchoscopy) 1. Nasal swab 2. Cough swab 3. Induced sputum after inhalation of hypertonic saline (NaCl 6%) 4. Bronchoalveolar lavage (BAL)
Primary Outcome Measures
NameTimeMethod
Sensitivity, specificity, positive and negative predicted value2 years

Sensitivity, specificity, positive and negative predicted value of different sampling methods

Secondary Outcome Measures
NameTimeMethod
Preference of methodQuestionnaire: day of sampling, Analysis: 2 years

If no differences are observed between sampling methods, which method would be preferred by the patient?

Pain experienced with any methodQuestionnaire: day of sampling, Analysis: 2 years

Is there any pain experienced? If so, how much? --\> VAS

© Copyright 2025. All Rights Reserved by MedPath